SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
LB Pharmaceuticals Inc Common Stock (LBRX) has a negative trailing P/E of -26.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -3.85%.
Criteria proven by this page:
- VALUE (60/100, Pass) — analyst target implies upside (+13.3%).
- Trailing Earnings Yield -3.85% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
- Analyst consensus target $33.00 (+13.3% upside) — modest upside expected.
Overall SharesGrow Score: 48/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — LBRX
Valuation Multiples
P/E (TTM)-26.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio2.17
P/S Ratio0.00
EV/EBITDA-17.9
Per Share Data
EPS (TTM)$-1.00
Book Value / Share$11.91
Revenue / Share$0.00
FCF / Share$-1.39
Yields & Fair Value
Earnings Yield-3.85%
Dividend Yield0.00%
Analyst Target$33.00 (+13.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2022 |
-4.3 |
0.00 |
-2.13 |
0.00 |
- |
| 2023 |
-9.8 |
0.17 |
-1.78 |
0.00 |
- |
| 2024 |
-1.0 |
0.00 |
-0.65 |
0.00 |
- |
| 2025 |
-22.3 |
0.24 |
1.87 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2022 |
$-4.05 |
$0.00 |
$-14.35M |
- |
| 2023 |
$-1.77 |
$0.00 |
$-6.28M |
- |
| 2024 |
$-17.83 |
$0.00 |
$-63.1M |
- |
| 2025 |
$-1.00 |
$0.00 |
$-25.21M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-3.90 |
$-4.63 – $-3.50 |
$0.00 |
$0.00 – $0.00 |
3 |
| 2027 |
$-3.97 |
$-4.32 – $-3.60 |
$0.00 |
$0.00 – $0.00 |
2 |
| 2028 |
$-4.09 |
$-5.32 – $-2.85 |
$0.00 |
$0.00 – $0.00 |
2 |
| 2029 |
$-5.00 |
$-5.00 – $-5.00 |
$52.3M |
$52.3M – $52.3M |
1 |
| 2030 |
$-3.52 |
$-3.52 – $-3.52 |
$172.13M |
$172.13M – $172.13M |
1 |
